Shareholders to Vote on Doubling Authorized Shares to 250M, Critical for Converting Recent $25M Preferred Stock Financing

summarizeSummary

Opus Genetics is asking shareholders to approve a 100% increase in authorized common stock to 250 million shares, a necessary step to convert a recent $25 million Series B Preferred Stock financing and provide flexibility for future capital needs.

check_boxKey Events · Financing and Capital Events · IRD

• Proposed Increase in Authorized Shares

  The company proposes to amend its Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125 million to 250 million shares.

• Enables Conversion of Recent $25M Financing

  This increase is required to permit the full conversion of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, issued in a $25 million private placement on February 13, 2026. Without approval, the Series B Preferred Stock cannot fully convert into common stock.

• Significant Potential Dilution

  As of March 5, 2026, 71,149,045 shares were outstanding. If all 250 million authorized shares were issued, including the 7.37 million from Series B conversion, the potential dilution for existing shareholders would be substantial.

• Future Capital Flexibility

  The additional authorized shares are intended to provide the company with flexibility for future financing needs, equity incentive plans, settlement of obligations, acquisitions, and other corporate purposes.

auto_awesomeAnalysis · IRD · Life Sciences

Opus Genetics is seeking shareholder approval to significantly increase its authorized common stock from 125 million to 250 million shares. This increase is crucial as it will enable the conversion of 7,374,632 shares of Series B Preferred Stock, which were recently issued in a $25 million private placement on February 13, 2026. Without this amendment, the company lacks sufficient authorized shares for the full conversion of the preferred stock, directly impacting the finalization of this capital raise. While the capital infusion is positive for the company's runway, the potential for substantial future dilution (over 250% if all authorized shares were issued) is a significant concern for existing shareholders. This vote is a critical step in the company's financing strategy and its ability to execute future capital-raising activities and strategic transactions.